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In the fifth season of Influenza Monitoring Vaccine 
Effectiveness in Europe (I-MOVE), we undertook a mul-
ticentre case–control study (MCCS) in seven European 
Union (EU) Member States to measure 2012/13 influ-
enza vaccine effectiveness against medically attended 
influenza-like illness (ILI) laboratory confirmed as 
influenza. The season was characterised by substan-
tial co-circulation of influenza B, A(H1N1)pdm09 and 
A(H3N2) viruses. Practitioners systematically selected 
ILI patients to swab ≤7 days of symptom onset. We 
compared influenza-positive by type/subtype to influ-
enza-negative patients among those who met the EU 
ILI case definition. We conducted a complete case 
analysis using logistic regression with study as fixed 
effect and calculated adjusted vaccine effectiveness 
(AVE), controlling for potential confounders (age, sex, 
symptom onset week and presence of chronic condi-
tions). We calculated AVE by type/subtype. Study sites 
sent 7,954 ILI/acute respiratory infection records for 
analysis. After applying exclusion criteria, we included 
4,627 ILI patients in the analysis of VE against influ-
enza B (1,937 cases), 3,516 for A(H1N1)pdm09 (1,068 
cases) and 3,340 for influenza A(H3N2) (730 cases). 
AVE was 49.3% (95% confidence interval (CI): 32.4 
to 62.0) against influenza B, 50.4% (95% CI: 28.4 to 
65.6) against A(H1N1)pdm09 and 42.2% (95% CI: 14.9 
to 60.7) against A(H3N2). Our results suggest an over-
all low to moderate AVE against influenza B, A(H1N1)
pdm09 and A(H3N2), between 42 and 50%. In this sea-
son with many co-circulating viruses, the high sample 
size enabled stratified AVE by type/subtype. The low 
estimates indicate seasonal influenza vaccines should 
be improved to achieve acceptable protection levels.
Introduction
The 2012/13 influenza season in Europe was charac-
terised by an extended season where the three influ-
enza viruses A(H1N1)pdm09, A(H3N2), B/Yamagata 
lineage all contributed substantially to morbidity 
although marked geographical differences were noted 
[1]. Currently, the best preventive method against influ-
enza is receipt of the influenza vaccine. The compo-
sition of the 2012/13 northern hemisphere influenza 
vaccine included A/California/7/2009 (H1N1)pdm09, A/
Victoria/361/2011 (H3N2) and B/Wisconsin/1/2010-like 
(Yamagata lineage) viruses. The A(H3N2) and influenza 
B components were changed from those of the 2011/12 
influenza season [2].
Influenza vaccine effectiveness (VE) studies are essen-
tial to monitor how the vaccine performs in the target 
populations. If VE estimates are available early in the 
season they can lead to additional preventive measures 
if they are low, such as stronger recommendations for 
antiviral treatment for those at risk of severe disease. 
Since 2008/09, using a European multicentre case–
control study, a component of the Influenza Monitoring 
Vaccine Effectiveness (I-MOVE) network, we have 
estimated the effectiveness of the seasonal and pan-
demic influenza vaccine to prevent medically attended 
influenza-like illness (ILI) laboratory confirmed as 
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influenza [3-6]. In February 2013, early influenza VE 
estimates from the multicentre case–control study for 
the 2012/13 influenza season by type/subtype were 
included among the VE estimates provided to the World 
Health Organization (WHO) for the vaccine strain selec-
tion meeting for the 2013/14 influenza vaccine: 78.2% 
(95% confidence interval (CI): 18.0 to 94.2) against 
influenza B, 62.1% (95% CI: -22.9 to 88.3) against A(H1)
pdm09, 41.9 (95% CI: −67.1 to 79.8) against A(H3N2) 
[7]. Estimates were also sent to other major bodies sup-
porting public health decision-making: The European 
Centre for Disease Prevention and Control and the 
European Medicines Agency. In this article we pre-
sent the 2012/13 end of season pooled VE estimates, 
from study sites in seven European Union (EU) Member 
States. The objective of the fifth I-MOVE multicentre 
case–control study was to provide pooled adjusted 
influenza VE estimates by influenza type/subtype and 
age group for the overall population and for the target 
group for vaccination. 
Methods
The seven study sites undertaking case–control stud-
ies included in the 2012/13 analysis were based in 
France, Germany, Ireland, Poland, Portugal, Romania 
and Spain. All study sites used the test-negative 
design; detailed methods on the I-MOVE multicentre 
case–control study are described elsewhere [4-6]. In 
summary, participating practitioners interviewed and 
carried out nasopharyngeal swabbing of all or of a sys-
tematic sample of patients presenting with influenza-
like illness (ILI) or acute respiratory infection (ARI); in 
France practitioners sampled ARI patients exclusively 
and in Germany in case of no patients consulting for 
ILI, practitioners sampled those consulting for ARI.
Practitioners from all study sites collected informa-
tion on date of symptom onset and date of swabbing, 
2012/13 seasonal influenza vaccination status, date 
and brand, 2011/12 seasonal influenza vaccination 
status, ILI symptoms, sex, presence of a chronic condi-
tion (including obesity, except Germany and Poland), 
number of hospitalisations for chronic conditions in 
the previous 12 months and pregnancy. Six study sites 
collected information on number of practitioner visits 
in the previous 12 months (not collected in Germany), 
five collected information on receipt of antivirals (not 
collected in Spain and France) and five on smoking sta-
tus (not collected in Germany and France). To identify 
individuals belonging to the target group for vaccina-
tion, four study sites included a specific question and 
three used variables such as age, chronic conditions, 
and pregnancy to enable their identification.
We included patients in the study if they met the EU 
ILI case definition (sudden onset of symptoms and at 
least one of the following four systemic symptoms: 
fever or feverishness, malaise, headache, myalgia; 
and at least one of the following three respiratory 
symptoms: cough, sore throat, shortness of breath), if 
they were swabbed ≤7 days of symptom onset, had no 
contraindications to influenza vaccination and did not 
receive antivirals prior to swabbing [8].
We defined the study period as at least 15 days after 
the beginning of the 2012/13 country-specific seasonal 
influenza vaccination campaigns and excluded controls 
that had symptom onset before the week of onset of 
the first influenza type/subtype case depending on the 
outcome used. We also dropped ILI patients present-
ing after the week of onset of the last influenza type/
subtype case depending on outcome used, after which 
there were at least two consecutive weeks with no fur-
ther influenza positive cases of this type/subtype.
Swabs were tested for influenza at the respective coun-
try’s National Influenza Reference Laboratory. In France 
and Spain, tests were also conducted in other labora-
tories participating in the National Influenza Sentinel 
Surveillance System. All the laboratories contributing 
to the National Influenza Sentinel Surveillance Systems 
are certified. At all study sites a subset of isolates 
were genetically and/or antigenically characterised. 
Details of laboratory viral detection, typing, subtyp-
ing and variant analysis performed in each country are 
described elsewhere [9].  
Among study participants fulfilling the inclusion crite-
ria, we defined a case as a patient who tested positive 
for influenza virus by reverse-transcription polymer-
ase chain reaction (RT-PCR) or culture. We classified 
patients with swabs testing negative for influenza 
virus as controls. 
We classified cases and controls as vaccinated if 
they had received at least one dose of 2012/13 sea-
sonal influenza vaccine at least 15 days before ILI 
symptom onset. All other patients were classified as 
unvaccinated.
Study sites sent their anonymised data to EpiConcept, 
where we pooled them and carried out a complete 
case analysis (where records with missing values were 
dropped). Using a one-stage method with study site 
as fixed effect in the model, we estimated the pooled 
influenza VE as 1 minus the odds ratio (OR) of being 
vaccinated in cases versus controls multiplied by 100. 
To test for heterogeneity by influenza type/subtype 
between study sites, we used Cochran’s Q-test and 
the I2 index [10]. In study sites with sample sizes large 
enough we used adjusted ORs and their standard error, 
otherwise we used the crude ORs. In study sites with 
no vaccinated cases, we reclassified one unvaccinated 
case as vaccinated chosen at random, in order to calcu-
late the OR and standard error. 
We used a logistic regression model to calculate VE 
including potential confounding factors: age (modelled 
as a restricted cubic spline with 4 knots [11]), sex, 
presence of at least one chronic condition (including 
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pregnancy and obesity where available) and week of 
symptom onset.
We calculated VE against influenza type/subtype and 
carried out stratified analyses by age group (0–14 
years, 15–59 years and ≥60 years). We categorised vac-
cines according to vaccine group: inactivated subunit 
egg-based, inactivated subunit cell-based, inactivated 
split virion egg-based and inactivated adjuvanted 
(squalene MF59) and calculated VE by influenza vac-
cine group, by age group and for the target group for 
vaccination.
In a sensitivity analysis we restricted to those swabbed 
within three days of symptom onset also and we also 
calculated VE adjusted by current smoking status and 
number of general practitioner (GP) visits in the pre-
vious 12 months (0–1 visits, 2–4 visits and ≥5 visits) 
among the five study sites collecting this informa-
tion. We calculated VE with those vaccinated within 14 
days of symptom onset excluded, instead of coded as 
unvaccinated. We also carried out a multiple imputa-
tion using chained equations to assess if there was 
any bias in dropping records with missing data. We 
used missing at random assumptions and indepen-
dently analysed 20 copies of the data using 30 cycles 
of regression. The variables included in the model to 
create the imputation database were the respective 
outcomes and the predictors: vaccination status for the 
2012/13 season, age group, sex, presence of chronic 
conditions and associated hospitalisations in the pre-
vious 12 months, 2011/12 seasonal vaccination sta-
tus, belonging to a target group for vaccination, delay 
between onset and swabbing, onset month and study 
site.
Results
The influenza season in the seven countries where the 
seven respective study sites were located in started 
and peaked at different times, as defined by national 
thresholds (Table 1). The season started earliest in 
Poland (week 47, 2012) and latest in Portugal, Romania 
and Spain (week 3, 2013). The peak of the influenza 
season varied from week 1, 2013 in Ireland to week 10, 
2013 in Portugal.
Study sites sent a total of 7,954 records of ILI/ARI 
patients for analysis (Figure 1). After applying exclu-
sion criteria, we included 4,627 ILI patients in the 
analysis of VE against influenza B (1,937 cases), 3,516 
in the analysis of VE against influenza A(H1N1)pdm09 
(1,068 cases) and 3,340 in the analysis of VE against 
influenza A(H3N2) (730 cases). The maximum weekly 
Table 1
Study details for the I-MOVE multicentre case–control study to measure 2012/13 influenza vaccine effectiveness, study sites 
in seven European Union Member States, ISO week 43 in 2012–ISO week 18 in 2013
Study site
Week/year 
of start of 
influenza 
seasona
Week/
year of 
peak of 
influenza 
seasona
Number of 
practitioners 
recruiting at 
least one ILI 
patientb
Number 
of ILI 
patientsb 
included 
in study
Inclusion period 
for the final 
analysis (ISO 
weeks/year)c
Number of included 
ILI patients positive 
for influenza and with 
known vaccination 
statusd
Number of included 
ILI patients negative 
for any influenza and 
with known vaccination 
statusd
Total Vaccinated Total Vaccinated
France 51/2012 5/2013 318 1,613 51/2012–15/2013 950 33 619 33
Germany 50/2012 8/2013 137 2,875 43/2012–18/2013 1,407 95 1,305 123
Ireland 50/2012 1/2013 21 264 48/2012–16/2013 167 10 96 10
Poland 47/2012 3/2013 4 54 49/2012–4/2013 24 0 30 0
Portugal 3/2013 10/2013 44 335 51/2012–15/2013 152 8 183 37
Romania 3/2013 8/2013 69 196 2/2013–17/2013 130 1 66 7
Spain 3/2013 8/2013 194 1,297 50/2012–16/2013 823 40 473 45
Total – – 787 6,634 43/2012–18/2013 3,653 187 2,772 255
ILI: Influenza-like illness; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; ISO: International Organization for Standardization. 
The study sites for the 2012/13 influenza vaccine effectiveness analysis were respectively located in the seven following European Union 
Member States: France, Germany, Ireland, Poland, Portugal, Romania and Spain.
a  According to the thresholds used to define the start of the influenza season in each of the countries. 
b  ILI patients meeting the European Union case definition, swabbed ≤7days after onset of symptoms within the study period.
c  From 15 days after the start of the vaccination campaign to week 18, 2013. We excluded controls with onset of symptoms in the weeks 
before the week of the first influenza case and after the week of the influenza case after which there were two or more consecutive weeks 
with no further cases in the study site. 
d  ILI patients included in the study, after excluding those with missing information on vaccination status or date of vaccination.
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Figure 1
Flowchart of data exclusion, I-MOVE multicentre case–control study to measure 2012/13 influenza vaccine effectiveness, 
study sites in seven European Union Member States, influenza season 2012/13
EU: European Union; ILI: influenza-like illness; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; ISO: International Organization 
for Standardization.
a Includes 6 influenza B+A(H1N1)pdm09 and 3 influenza B+A(H3N2) co-infections.
b Includes 6 influenza B+A(H1N1)pdm09 and 7 A(H1N1)pdm09+A(H3N2) co-infections.
c Includes 3 influenza B+A(H3N2)pdm09 and 7 A(H1N1)pdm09+A(H3N2) co-infections.
d Includes 5 influenza B+A(H1N1)pdm09 and 3 influenza B+A(H3N2) co-infections.
e Includes 5 influenza B+A(H1N1)pdm09 and 7 A(H1N1)pdm09+A(H3N2) co-infections.
 
 Cases: 978e 
(N=150) 
Records received 
7,954 
Excluding records: 
• Persons with contraindications against vaccination (N=2) 
• Persons administered antivirals prior to swabbing (N=9) 
• Persons with missing laboratory results (N=7) 
• Persons with missing onset date (N=226) 
• With date of onset <15 days after begin of vaccination campaign (N=0) 
• Not meeting the EU ILI case deﬁnition (N=443) or EU ILI status unknown (N=400) 
• With interval between onset of symptoms and swabbing >7 days (N=114) 
   • Excluding patients presenting before ISO week of ﬁrst type/subtype-speciﬁc inﬂuenza case and 
after ISO week of last type/subtype-speciﬁc inﬂuenza case after which there are two consecutive 
weeks of no cases (weeks of symptom onset, by country)  
• Excluding inﬂuenza positive records of diﬀerent type/subtype  
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(N=2,529) (N=2,784) 
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(N=144) 
• Excluding persons with missing information on age, sex or chronic disease  
• Excluding persons with missing 2012/13 inﬂuenza vaccination status or date 
 
(N=73) (N=64) (N=60) 
4,627 
Cases: 1,937a 
Controls: 2,690 
3,516 
Cases: 1,068b 
Controls: 2,448 
3,340 
Cases: 730c 
Controls: 2,610 
4,344 
Cases: 1,860d 
Controls: 2,484 
3,249 
Cases: 978e 
Controls: 2,271 
 
3,057 
Cases: 672c 
Controls: 2,385 
 
 
4,271 
Cases: 1,842 
Controls: 2,429 
 
3,185 
Cases: 962 
Controls: 2,223 
 
2,997 
Cases: 657 
Controls: 2,340 
6,753 
Inﬂuenza B analysis 
6,753 
Inﬂuenza A(H1N1)pdm09 analysis 
6,753 
Inﬂuenza A(H3N2) analysis 
6,753 
 
Inﬂuenza B analysis 
4,344 
Inﬂuenza A(H1N1)pdm09 analysis 
3,516 
 
Inﬂuenza A(H3N2) analysis 
3,340 
• Excluding records with missing vaccination brand  
Inﬂuenza A(H1N1)pdm09 analysis 
3,249 
Inﬂuenza A(H3N2) analysis 
3,057 
Inﬂuenza B analysis 
4,627 
Excluding records with missing data for complete case analysis    
Excluding records for pooled analysis
Excluding records with missing vaccination brand for vaccine group analysis    
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number of cases recruited by type/subtype occurred at 
different times in the study (Figure 2).
After excluding patients with missing information on 
2012/13 seasonal vaccination status or date, age, sex 
or presence of chronic condition, we included 4,344, 
3,249 and 3,057 individuals for the complete case anal-
ysis of VE against influenza B, influenza A(H1N1)pdm09 
and A(H3N2) respectively.
The median age was 15 years for influenza B cases 
(interquartile range (IQR): 7–43 years), 31 years for 
A(H1N1)pdm09 cases (IQR: 10–46 years) and 20 years 
for A(H3N2) cases (IQR: 5–46 years). Controls had a 
median age of 22 years (IQR: 4–45 years).
Among controls, 18% had at least one chronic condi-
tion, compared to 15%, 15% and 13% of influenza B, 
A(H1N1)pdm09 and A(H3N2) cases respectively. The 
proportion vaccinated with the 2012/13 influenza vac-
cine was 9% among controls, 5% among influenza B 
cases, 5% among A(H1N1)pdm09 cases and 7% among 
A(H3N2) cases (Table 2). 
Among controls, 22% belonged to the target group for 
vaccination compared to 19%, 20%, and 20% of influ-
enza A(H1N1)pdm09, influenza A(H3N2) and influenza 
B cases respectively (Table 2).
Overall 90% of controls were swabbed within three 
days of symptom onset compared to 91%, 90% and 
86% of influenza A(H1N1)pdm09, influenza A(H3N2) 
and influenza B, cases respectively.
Among 331 vaccinated participants with known type 
of vaccine, 64% (213/331) had received split virion 
vaccine (note: one participant was co-infected with 
influenza A(H3N2) and influenza B). The proportion 
receiving split virion vaccine by country was: 0% (0/8) 
in Romania, 56% (87/156) in Germany, 71% (30/42) in 
France, 73% (62/85) in Spain, 76% (19/25) in Portugal 
and 100% (15/15) in Ireland. Ireland, however, was 
omitted from the vaccine type analysis as only one 
vaccine type was available. Four study participants in 
Spain and two in Germany had received an adjuvanted 
vaccine and one participant in Germany received a 
cell-mediated subunit vaccine. All others, including all 
eight vaccinated participants from Romania received 
an egg-derived subunit vaccine.
The Q test and I2 index  testing for heterogeneity of VE 
between study sites suggested no heterogeneity for 
influenza A(H1N1)pdm09 (p=0.849, I2=0%), low het-
erogeneity for influenza B, (p=0.249, I2=24.7%) and 
low to moderate heterogeneity for influenza A(H3N2) 
(p=0.168, I2=37.9%).
Influenza VE adjusted by onset week, presence of 
chronic conditions age and sex was 49.3% (95% CI: 
32.4 to 62.0) against influenza B, 50.4% (95% CI: 
28.4 to 65.6) against influenza A(H1N1)pdm09 and 
42.2% (95% CI: 14.9 to 60.7) against influenza A(H3N2) 
(Table 3). 
Among those aged 0 to 14 years, the adjusted VE was 
22.3% (95% CI: -37.0 to 55.9) against influenza B, 
36.5% (95% CI: -44.1 to 72.0) against influenza A(H1N1)
pdm09 and 36.1% (95% CI: -41.1 to 71.0) against influ-
enza A(H3N2). Among those aged 15 to 59 years, the 
adjusted VE was 63.6% (95% CI: 42.1 to 77.1) against 
influenza B, 55.6% (95% CI: 28.3 to 72.5) against influ-
enza A(H1N1)pdm09 and 43.6% (95% CI: -3.8 to 69.4) 
against influenza A(H3N2).The sample size did not ena-
ble measuring adjusted VE among those aged 60 years 
and above. The crude VE in this age group was 44.0% 
(95% CI: 8.9 to 65.5) against influenza B, 59.1% (95% 
CI: 14.3 to 80.5) against influenza A(H1N1)pdm09 and 
37.3% (95% CI: -13.0 to 65.3) against influenza A(H3N2).
Due to small numbers, VE for the inactivated subunit 
cell-based vaccine and the adjuvanted vaccine were not 
estimated. The adjusted VE for the inactivated subunit 
vaccine group was 47.8% (95% CI: 12.0 to 69.0) against 
influenza B, 68.8% (95% CI: 32.3 to 85.6) against influ-
enza A(H1N1)pdm09 and 63.1% (95% CI: 20.1 to 82.9) 
against influenza A(H3N2). The adjusted VE for the 
inactivated split virion vaccine group was 52.5% (95% 
CI: 29.5 to 68.0) against influenza B, 48.9% (95% CI: 
Figure 2
Number of ILI cases included in the pooled analysis by 
influenza type/subtype and week of symptom onset, 
I-MOVE multicentre case–control study to measure 
2012/13 influenza vaccine effectiveness, influenza season 
2012/13 (n=6,609) 
ILI: influenza-like illness; I-MOVE: Influenza Monitoring Vaccine 
Effectiveness in Europe; ISO: International Organization for 
Standardization.
The seven European Union Member State study sites were 
respectively located in France, Germany, Ireland, Poland, Portugal, 
Romania and Spain.
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Table 2
Details for influenza B (n=1,937), A(H3N2) (n=730), A(H1N1)pdm09 (n=1,068) cases and controls (n=2,874) included in the 
2012/13 season trivalent influenza vaccine effectiveness analysis, I-MOVE multicentre case–control study in seven European 
Union study sites, ISO week 43 in 2012–ISO week 18 in 2013, influenza season 2012/13
Variables
Number of test-
negative controlsa/
total (%)
Number of influenza B 
casesb,c/total (%)
Number of influenza 
A(H1N1)pdm09 
casesb,d/total (%)
Number of influenza 
A(H3N2) casesc,d/total 
(%)
Age groups in years
0–4 739/2,871 (26) 290/1,937 (15) 162/1,068 (15) 169/729 (23)
5–14 474/2,871 (17) 650/1,937 (34) 160/1,068 (15) 154/729 (21)
15–64 1,396/2,871 (49) 860/1,937 (44) 693/1,068 (65) 328/729 (45)
≥60 262/2,871 (9) 137/1,937 (7) 53/1,068 (5) 78/729 (11)
Sex–Female 1,458/2,854 (51) 965/1,933 (50) 562/1,059 (53) 355/727 (49)
Days between onset of symptoms and swabbing
0 220/2,874 (8) 73/1,937 (4) 61/1,068 (6) 58/730 (8)
1 1,214/2,874 (42) 652/1,937 (34) 448/1,068 (42) 306/730 (42)
2 714/2,874 (25) 626/1,937 (32) 308/1,068 (29) 201/730 (28)
3 429/2,874 (15) 324/1,937 (17) 155/1,068 (15) 93/730 (13)
4–7 297/2,874 (10) 262/1,937 (14) 96/1,068 (9) 72/730 (10)
Seasonal vaccination, 2012/13e 255/2,772 (9) 94/1,898 (5) 48/1,031 (5) 47/699 (7)
2012/13 influenza vaccine group
Inactivated subunit egg-based 68/2,713 (3) 25/1,879 (1) 9/1,013 (1) 9/683 (1)
Inactivated split virion egg-based 123/2,713 (5) 48/1,879 (3) 21/1,013 (2) 22/683 (3)
Inactivated subunit cell-based 1/2,713 (0) 0/1,879 (0) 0/1,013 (0) 0/683 (0)
Inactivated adjuvanted (squalene MF59) 4/2,713 (0) 2/1,879 (0) 0/1,013 (0) 0/683 (0)
At least one chronic condition 495/2,733 (18) 278/1,896 (15) 154/1,014 (15) 91/690 (13)
At least one hospitalisation in the previous 
12 months for chronic condition 29/2,519 (1) 18/1,816 (1) 9/947 (1) 5/632 (1)
Belongs to target group for vaccination 624/2,801 (22) 376/1,916 (20) 199/1,045 (19) 140/707 (20)
Study sites
France 643/2,874 (22) 534/1,937 (28) 234/1,068 (22) 179/730 (25)
Germany 1,383/2,874 (48) 519/1,937 (27) 508/1,068 (48) 471/730 (65)
Ireland 96/2,874 (3) 119/1,937 (6) 17/1,068 (2) 29/730 (4)
Poland 30/2,874 (1) 1/1,937 (0) 22/1,068 (2) 0/730 (0)
Portugal 183/2,874 (6) 66/1,937 (3) 80/1,068 (7) 6/730 (1)
Romania 66/2,874 (2) 74/1,937 (4) 52/1,068 (5) 2/730 (0)
Spain 473/2,874 (16) 624/1,937 (32) 155/1,068 (15) 43/730 (6)
I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; ISO: International Organization for Standardization.
Denominators of the fractions vary in each category of variables when the information in question is not known for all cases and/or controls. 
36 influenza A cases that were not subtypable are not included in the Table.
a  Controls from ‘any influenza’ analysis used.
b  Six influenza cases positive for both influenza B and for influenza A(H1N1)pdm09 were included in the analysis.
c  Three influenza cases positive for both influenza A(H3N2) and for influenza B were included in the analysis.
d  Seven influenza cases positive for both influenza A(H3N2) and for influenza A(H1N1)pdm09 were included in the analysis.
e Vaccination more than 14 days before onset of influenza-like illness symptoms.
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Table 3a
Pooled crude and adjusted seasonal vaccine effectiveness against laboratory-confirmed influenza by influenza type/subtype, 
overall and among target groups for vaccination, I-MOVE multicentre case–control study in seven European Union study 
sites to measure 2012/13 influenza vaccine effectiveness, ISO week 43 in 2012–ISO week 18 in 2013, influenza season 2012/13
Analysis scenarios, population included
Influenza B
VE (95%CI)
Influenza A(H1N1)pdm09
VE (95%CI)
Influenza A(H3N2)
VE (95%CI) 
Primary analysis
All age groupsa
N (cases/vaccinated; controls/vaccinated) 4,344 (1,860/92; 2,484/236) 3,196 (978/44; 2,218/214) 3,012 (672/46; 2,340/212)
Crude (study site as fixed effect) 46.5 (30.9 to 58.6) 56.1 (38.6 to 68.7) 22.5 (-8.6 to 44.7)
Adj. for onset week 50.2 (35.4 to 61.6) 57.5 (40.2 to 69.8) 29.1 (-0.5 to 50.0)
Adj. for sex 46.6 (31.0 to 58.7) 56.2 (38.7 to 68.7) 22.4 (-8.7 to 44.6)
Adj. for chronic condition 43.2 (25.9 to 56.5) 54.0 (34.9 to 67.5) 17.4 (-17.2 to 41.8)
Adj. for age 45.7 (28.3 to 59.0) 50.3 (28.9 to 65.2) 38.6 (11.1 to 57.5)
Adj. for onset week, age 50.1 (33.8 to 62.5) 51.9 (30.9 to 66.6) 45.7 (20.5 to 63.0)
Adj. for onset week, sex 50.3 (35.5 to 61.7) 57.6 (40.4 to 69.9) 29.0 (-0.6 to 49.9)
Adj. for onset week, chronic condition, age, sex 49.3 (32.4 to 62.0) 50.4 (28.4 to 65.6) 42.2 (14.9 to 60.7)
0–14 year-oldsb
N (cases/vaccinated; controls/vaccinated) 1,969 (905/26; 1,064/40) 1,210 (292/8; 918/35) 1,252 (296/9; 956/34)
Crude 8.0 (-54.4 to 45.2) 30.9 (-52.0 to 68.6) 28.0 (-53.2 to 66.2)
Adj. for onset week, chronic condition, age, sex 22.3 (-37.0 to 55.9) 36.5 (-44.1 to 72.0) 36.1 (-41.1 to 71.0)
15–59 year-oldsc
N (cases/vaccinated; controls/vaccinated) 1,994 (824/28; 1,170/95) 1,709 (636/25; 1,073/85) 1357 (303/15; 1,054/85)
Crude 55.6 (30.8 to 71.6) 52.9 (25.5 to 70.3) 41.0 (-4.6 to 66.8)
Adj. for onset week, chronic condition, age, sex 63.6 (42.1 to 77.1) 55.6 (28.3 to 72.5) 43.6 (-3.8 to 69.4)
≥60 year-olds
N (cases/vaccinated; controls/vaccinated) 362 (131/38; 231/100) 266 (50/11; 216/94) 277 (73/22; 204/89)
Crude 44.0 (8.9 to 65.5) 59.1 (14.3 to 80.5) 37.3 (-13.0 to 65.3)
Adj. for onset week, chronic condition, age, sex Too few cases Too few cases Too few cases
Analysis by vaccine groupd
N (cases/vaccinated subunit/vaccinated split virion; 
controls/vaccinated subunit/vaccinated split virion)
4,058 (1,724/24/44; 
2,334/61/106)
3,038 (945/8/20; 
2,093/55/99)
2,830 (630/9/20; 
2,200/54/99)
Crude subunit
Crude split virion
41.0 (3.7 to 63.9)
48.6 (25.7 to 64.4)
72.0 (40.7 to 86.8)
55.0 (26.6 to 72.4)
47.0 (-8.9 to 74.2)
19.0 (-33.5 to 50.9)
Fully adjustede subunit
Fully adjustede split virion
47.8 (12.0 to 69.0)
52.5 (29.5 to 68.0)
68.8 (32.3 to 85.6)
48.9 (13.7 to 69.8)
63.1 (20.1 to 82.9)
41.7 (-1.3 to 66.5)
Adj: adjusted; CI: confidence interval; GP: general practitioner; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; ISO: 
International Organization for Standardization; obs: observations; VE: vaccine effectiveness.
a  Week 46 dropped (45 obs) for influenza A(H3N2); week 48 dropped (53 obs) for influenza A(H1N1).
b  Weeks 48 and 13 dropped (27 obs) for influenza A(H1N1); weeks 46, 47 and weeks 14–16 and Romania dropped (119 obs) for influenza 
A(H3N2).
c  Week 47 dropped (19 obs) for influenza B; weeks 48 and 15 dropped (37 obs) for influenza A(H1N1); weeks 43–46 dropped (52 obs) for 
influenza A(H3N2).
d  Ireland excluded as only one vaccine group available (split virion). Records with adjuvanted or inactivated subunit cell-based vaccine group 
excluded due to very low sample sizes (8 and 1 respectively). Unknown or missing vaccine group excluded from analysis.
e Adjusted for onset week, chronic condition, age and sex.
f  Weeks 18 and 47 dropped for influenza B (14 obs). Weeks 47,48 and 50 dropped for A(H1N1) (36 obs). October dropped for A(H3N2) – 
adjusted by onset month, not week, due to small sample size (3 obs dropped). 
g  Week 48 dropped for influenza A(H1N1) (47 obs). Week 46 dropped for influenza A(H3N2) (40 obs).
h  Week 48 dropped for influenza A(H1N1) (53 obs). Week 46 dropped for A(H3N2) (45 obs).
i  Numbers of vaccinated and unvaccinated are approximate, due to the nature of the imputed database. Week 46 dropped for influenza 
A(H3N2) (52 obs). Adjusted for age group (10 year age bands), sex, presence of chronic condition and week of symptom onset. 
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Table 3b
Pooled crude and adjusted seasonal vaccine effectiveness against laboratory-confirmed influenza by influenza type/subtype, 
overall and among target groups for vaccination, I-MOVE multicentre case–control study in seven European Union study 
sites to measure 2012/13 influenza vaccine effectiveness, ISO week 43 2012–ISO week 18 2013, influenza season 2012/13
Analysis scenarios, population included Influenza BVE (95%CI)
Influenza A(H1N1)pdm09
VE (95%CI)
Influenza A(H3N2)
VE (95%CI) 
Sensitivity analysis
Restricted to target group for vaccinationf
N (cases/vaccinated; controls/vaccinated) 875 (356/69; 519/155) 648 (184/29; 464/142) 593 (126/29; 467/139)
Crude 40.7 (17.2 to 57.6) 55.8 (30.4 to 71.9) 23.2 (-22.9 to 52.0)
Adj. for onset week, chronic condition, age, sex 43.4 (17.9 to 61.0) 35.7 (-6.0 to 61.0) 39.0 (-3.4 to 63.9)
Restricted to those with delay onset and swabbing <4 daysg
N (cases/vaccinated; controls/vaccinated) 3,855 (1,609/79; 2,246/196) 2,912 (894/40; 2,018/178) 2,721 (609/39; 2,112/174)
Crude 40.3 (21.1 to 54.8) 51.9 (31.3 to 66.3) 20.1 (-15.3 to 44.6)
Adj. for onset week, chronic condition, age, sex 45.1 (24.9 to 59.8) 47.8 (23.2 to 64.6) 40.3 (9.1 to 60.8)
Those vaccinated <15 days excludedh
N (cases/vaccinated; controls/vaccinated) 4,336 (1,858/92; 2,478/236) 3,190 (978/44; 2,212/214) 3,002 (670/46; 2,332/212)
Crude 46.6 (31.0 to 58.7) 56.3 (38.8 to 68.8) 22.6 (-8.5 to 44.8)
Adj. for onset week, chronic condition, age, sex 49.6 (32.8 to 62.2) 50.7 (28.9 to 65.9) 42.3 (15.0 to 60.8)
Adjusting by GP visits and smoking (Ireland, Poland, Portugal, Romania and Spain)
N (cases/vaccinated; controls/vaccinated) 1,678 (875/39; 803/97) 1,105 (319/15; 786/93) 684 (79/5; 605/73)
Crude 62.5 (44.3 to 74.7) 63.5 (35.5 to 79.4) 47.3 (-37.4 to 79.8)
Adj. for onset week, chronic condition, age, sex 62.4 (41.0 to 76.1) 48.7 (3.3 to 72.8) Too few cases
Adj. for onset week, chronic condition, age, sex, smoking 62.3 (40.7 to 76.0) 48.7 (3.2 to 72.8) Too few cases
Adj. for onset week, chronic condition, age, sex, GP visits 60.0 (37.0 to 74.6) 46.0 (-2.0 to 71.4) Too few cases
Adj. for onset week, chronic condition, age, sex, 
smoking, GP visits 59.9 (36.8 to 74.6) 45.9 (-2.1 to 71.4) Too few cases
Imputed analysisi
N (cases/vaccinated; controls/vaccinated) 4,993 (2,016/101; 2,977/282) 3,842 (1,138/54; 2,704/258) 3,652 (793/55; 2,859/262)
Crude 46.2 (31.4 to 57.8) 53.4 (36.7 to 65.7) 24.7 (-4.9 to 45.9)
Fully adjustede 48.9 (33.0 to 61.1) 48.1 (27.3 to 63.0) 48.2 (23.8 to 64.8)
Adj: adjusted; CI: confidence interval; GP: general practitioner; I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe; ISO: 
International Organization for Standardization; obs: observations; VE: vaccine effectiveness.
a  Week 46 dropped (45 obs) for influenza A(H3N2); week 48 dropped (53 obs) for influenza A(H1N1).
b  Weeks 48 and 13 dropped (27 obs) for influenza A(H1N1); weeks46, 47 and weeks 14–16 and Romania dropped (119 obs) for influenza 
A(H3N2).
c  Week 47 dropped (19 obs) for influenza B; weeks 48 and 15 dropped (37 obs) for influenza A(H1N1); weeks 43–46 dropped (52 obs) for 
influenza A(H3N2).
d  Ireland excluded as only one vaccine group available (split virion). Records with adjuvanted or inactivated subunit cell-based vaccine group 
excluded due to very low sample sizes (8 and 1 respectively). Unknown or missing vaccine group excluded from analysis.
e Adjusted for onset week, chronic condition, age and sex.
f  Weeks 18 and 47 dropped for influenza B (14 obs). Weeks 47,48 and 50 dropped for A(H1N1) (36 obs). October dropped for A(H3N2) – 
adjusted by onset month, not week, due to small sample size (3 obs dropped). 
g Week 48 dropped for influenza A(H1N1) (47 obs). Week 46 dropped for influenza A(H3N2) (40 obs).
h  Week 48 dropped for influenza A(H1N1) (53 obs). Week 46 dropped for A(H3N2) (45 obs).
i  Numbers of vaccinated and unvaccinated are approximate, due to the nature of the imputed database. Week 46 dropped for influenza 
A(H3N2) (52 obs). Adjusted for age group (10 year age bands), sex, presence of chronic condition and week of symptom onset. 
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13.7 to 69.8) against influenza A(H1N1)pdm09 and 
41.7% (95% CI: -1.3 to 66.5) against influenza A(H3N2). 
The adjusted VE for the inactivated subunit vaccine 
group was 28.9% (95% CI: -60.6 to 68.5), 68.5% (95% 
CI: 32.6 to 85.3) and 64.6% (95% CI: 21.6 to 84.0) for 
the 0 to 14 year-olds, 15 to 59 year-olds and those aged 
60 and older respectively (Figure 3). The adjusted VE 
for the inactivated split virion vaccine group was 12.2% 
(95% CI: -85.6 to 58.5), 63.7% (95% CI: 39.7 to 78.2) 
and 54.1% (95% CI: 16.8 to 74.7) for the 0 to 14 year-
olds, 15 to 59 year-olds and those aged 60 and older 
respectively.
Discussion
In the 2012/13 influenza season, all the I-MOVE multi-
centre case–control VE adjusted point estimates were 
below 70%. The design of the case–control study, which 
involved a multicentre approach, enabled to obtain a 
sample size large enough to calculate adjusted VE with 
reasonable precision by age group and type/subtype 
in this season with significant proportions of influenza 
B and both influenza A subtypes circulating in Europe.
Adjusted VE estimates against influenza type/subtype 
for all ages were lowest for influenza A(H3N2) and high-
est for A(H1N1)pdm09. 
The obtained VE estimates by age group suggested 
differences in terms of age. Indeed, VE estimates 
were slightly higher among 15 to 59 year-olds while 
VE point estimates among children aged 0 to 14 years 
were low, with the lowest VE against influenza B. Two 
doses of vaccine are often recommended for children 
up to a certain age, usually before nine years of age, 
however information on number of doses received was 
not collected, so the results need to be interpreted 
with caution. Among the elderly, there were too few 
cases included in the study to estimate adjusted VE, 
despite GPs from five study sites including all elderly 
consulting for ILI in the study. The crude estimates 
however, suggest low VE against influenza B and influ-
enza A(H3N2). Low VE among the elderly was also seen 
this season in Denmark (in mainly a hospital setting) 
and against A(H3N2) in the United States in the early 
adjusted VE estimates [12,13]. Influenza A(H1N1)pdm09 
was less common than A(H3N2) and influenza B among 
the elderly in this study.
In four study sites, sampling schemes were different 
for elderly and other age groups. Therefore in analyses 
where it is not possible to stratify type/subtype-spe-
cific estimates further by age group, incorporating, in 
the future, a sampling fraction by age group and site 
may correct for any oversampling of a given age group 
by study site. This could render the comparison of 
results between countries and pooled estimates more 
accurate.
The analysis of VE by vaccine group suggested some 
differences between inactivated subunit and split 
virion vaccine types for VE against influenza A(H1N1)
pdm09 and influenza A(H3N2), although no differences 
were statistically significant. Some of the vaccines tar-
geted specific age groups, e.g. only the elderly, or only 
children. So the observed differences in VE may be due 
to differences in ages of persons using these vaccines. 
Again, an analysis by influenza type/subtype, age 
group and vaccine group was not possible due to low 
sample sizes. However an age-specific analysis of VE 
by vaccine group against any influenza showed smaller 
differences in adjusted VE of subunit and split virion 
vaccines among the different age groups. 
Data completeness was good, with only between six 
and 10% of observations dropped for the type/sub-
type-specific complete case analyses. The multiple 
imputation sensitivity analysis showed very similar VE 
estimates to the complete case analysis for influenza 
B and influenza A(H1N1)pdm09), suggesting no bias 
was introduced by missing values for these viruses. 
The imputed analysis suggested a slightly higher VE 
for influenza A(H3N2), indicating there may be a small 
bias in the missing data for A(H3N2). There is a higher 
proportion of children aged under five years among 
influenza A(H3N2) cases in this study and there is a 
higher proportion of missing values in the age group 
0 to 4 years. However practitioners are blinded to the 
outcome in this study design, so there should be no 
reason for differential incompleteness of data for cases 
and controls.
Figure 3
Pooled adjusted seasonal vaccine effectiveness by vaccine 
group against any laboratory-confirmed influenza by age 
group, I-MOVE multicentre case–control study in seven 
European Union study sites, ISO week 43 in 2012–ISO 
week 18 in 2013, influenza season 2012/13
I-MOVE: Influenza Monitoring Vaccine Effectiveness in Europe;  
ISO: International Organization for Standardization.
Below the X axis, the two numbers in parentheses for each 
vaccine type indicate the following: the first number represents 
all vaccinated with the vaccine group, while the second number 
represents the cases vaccinated: (N vaccinated; cases vaccinated).
The seven European Union study sites were respectively located in 
France, Germany, Ireland, Poland, Portugal, Romania and Spain.
28.9 
12.2  
68.5 63.7 64.6 
54.1
0
10
20
30
40
50
60
70
80
90
100
Subunit
(39;13)
Split virion
(33;21)
Subunit
(32;11)
Split virion
(70;27)
Subunit
(39;17)
Split virion
(82;34)
0–14 years (N=2,553) 15–59 years (N=2,755)  ≥60 years (N=419)
Va
cc
in
e 
eﬀ
ec
tiv
en
es
s 
(V
E)
 %
 
Vaccine type (N vaccinated; cases vaccinated) and age groups
10 www.eurosurveillance.org
Study sites collected potentially important information 
on positive and negative confounders [14]. Overall the 
magnitude of confounding was small for VE estimates 
against influenza B and A(H1N1)pdm09 (<3% and <6% 
absolute difference between crude and adjusted VE 
estimates for all ages respectively). Confounding was 
much greater for VE against influenza A(H3N2), with 
around 20% absolute difference, mainly due to the age 
adjustment. Information on smoking and practitioner 
visits in the previous 12 months was not collected 
by two study sites, however the sensitivity analysis 
restricted to the five study sites collecting these vari-
ables, suggests no major change in VE following inclu-
sion (<3% absolute difference).
Influenza type/subtype VE estimates varied by study 
site (data not shown). An analysis of heterogeneity 
using the I2 and Cochrane’s Q test showed no, low or 
moderate heterogeneity between study sites depend-
ing on type/subtype, none of which was statistically 
significant. A possible reason for heterogeneity may be 
different age distributions by study site among circu-
lating influenza type/subtypes. However an analysis of 
heterogeneity by age group and type/subtype together 
was not possible due to the small sample size. Ideally 
we need a large sample size by study site to carry out 
detailed study site-specific analyses; this will also 
enable a two-stage pooled analysis [15]. Other reasons 
for heterogeneity may include use of different vaccine 
brands and different healthcare seeking behaviour by 
study site.
Adjusted VE estimates among the target groups for 
vaccination were similar compared to the overall popu-
lation for influenza B and A(H3N2), however lower for 
influenza A(H1N1)pdm09, although confidence inter-
vals overlap. Influenza A(H1N1)pdm09 cases belong-
ing to the target group for vaccination had a higher 
proportion of younger people with chronic conditions 
than other influenza type/subtypes. This suggests that 
the vaccine may not protect as well against influenza 
A(H1N1)pdm09 among those who are vulnerable to 
complications.
The inclusion weeks for the 2012/13 study ranged 
from week 43 2012 to week 18 2013, making this a 
very extended study period compared to previous 
I-MOVE multicentre case–control studies [3-6]. The 
ratio of controls to cases varied along the season, with 
a higher ratio of controls to cases at the very begin-
ning of the study. An analysis restricted to peak weeks 
(weeks 1–12, 2013) showed very similar type/subtype-
specific VE, suggesting that this season, there was no 
bias introduced by including periods with a high ratio 
of controls to cases (data not shown). 
In the 2011/12 influenza season, the I-MOVE study 
looked at waning of vaccine-induced protection later 
in the season. In 2012/13, no vaccine-related waning 
of protection against A(H1N1) was evident, although 
sample sizes were low. Sample sizes for A(H3N2) were 
also too low to draw conclusions. For influenza B, there 
may have been some suggestion of waning of protec-
tion with more days between vaccination and onset of 
symptoms, however sample sizes are also too low to 
draw conclusions (data not shown).
While the test-negative design is commonly used in 
vaccine effectiveness studies, it remains a study design 
that needs to be validated [16-19]. Assumptions behind 
this study design and other biases associated with the 
test negative study design (e.g. representativeness of 
the test negative controls with regards the vaccine cov-
erage of the source population of cases, role of other 
ARI virus infections among the control group, etc.) 
have been described elsewhere [20-24]. Larger sample 
sizes are needed to perform robust validation analyses 
to determine if controls properly reflect the vaccine 
coverage of the source population for cases in general 
and over time.
The predominant influenza B lineage circulating in 
the 2012/13 influenza season in Europe was the B/
Yamagata lineage, which was also the vaccine virus lin-
eage [1]. Among the 1,860 influenza B cases included 
in the study, 694 (37.3%) specimens were ascribed 
to a lineage; 630 of these (90.7%) were influenza B/
Yamagata lineage (data not shown). Because of lim-
ited information on influenza B lineage in the study, 
we were unable to estimate VE by lineage, which 
would be important in the context of the introduc-
tion of the quadrivalent vaccines. Throughout the 
2012/13 season in Europe, B/Yamagata-lineage viruses 
from an antigenically distinguishable genetic clade 
from the vaccine virus clade have increasingly been 
detected [1]. These are from clade 2 represented by B/
Massachusetts/2/2012, which is a recommended vac-
cine component for the 2013/14 influenza vaccine [25]. 
While this may explain some of the lower VE estimates 
for influenza B in our study, we do not have virological 
data on an individual level to test this hypothesis.
The I-MOVE multicentre case–control study provided 
adjusted type/subtype-specific VE estimate early 
in this season, as did other studies [7,12,13,26-29]. 
The information was shared with WHO in time for the 
2013/14 influenza vaccine composition meeting in 
February 2013. Early adjusted VE estimates for influ-
enza B were higher than the final season adjusted 
estimates (78.2% vs. 49.3%), as well as for influenza 
A(H1N1)pdm09 (62.1% vs. 50.4%). Estimates for influ-
enza A(H3N2) remained similar (41.9% vs. 42.2%). 
Differences between early and overall estimates may 
be due to different proportions of cases occurring by 
age group over time; however this cannot be verified 
as sample sizes were too small to provide early type/
subtype estimates stratified by age. This strongly sug-
gests that effort should be made worldwide to increase 
the sample size for precise and stratified early and 
overall estimates each season.
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In conclusion, our estimates suggest that the 2012/13 
influenza vaccine has low to moderate effectiveness in 
preventing medically attended laboratory-confirmed 
influenza, with varying effectiveness in different 
age groups. In a season with the co-circulation three 
influenza types and subtypes, the large sample size 
achieved by the multicentre case–control study was 
necessary to provide the important age-specific esti-
mates. However an even greater sample size is needed 
to provide robust results among the elderly and to 
provide age group-specific estimates by type/subtype 
and vaccine type. While the vaccine remains the best 
method of protection against influenza, the low esti-
mates emphasise the need for an improved influenza 
vaccine. Influenza VE studies worldwide need to con-
tinue with sample sizes large enough to enable precise 
stratified estimates in order to better understand the 
mechanisms for varying VE by season and age groups.
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